1523 - SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety/Efficacy of AZD0486 as Monotherapy or in Combination With Acalabrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Primary Author / Presenter(s)

Matthew S. Davids, MD, MMSc

Director, Clinical Research, Division of Lymphoma; Associate Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

TE

Toby A. A. Eyre, MRCP, FRCPath, MD

Consultant Haematologist
Churchill Hospital, Oxford University
Oxford, England, United Kingdom
MS

Matthew Stankowicz, PharmD, BCOP

AstraZeneca
Gaithersburg, Maryland, United States
NJ

Nikolaus Jahn, MD

AstraZeneca
South San Francisco, California, United States
RM

Raghuveer Mali, PhD

AstraZeneca
South San Francisco, California, United States
XZ

Xu (Sue) Zhu, PhD

AstraZeneca
Waltham, Massachusetts, United States
YL

Yuyin Liu, PhD

AstraZeneca
Wilmington, Delaware, United States
FS

Firasath Ali Syed, MS

AstraZeneca
South San Francisco, California, United States
MA

Makhdum Ahmed, MD, PhD

AstraZeneca
Waltham, Massachusetts, United States
JR

Joanna Rhodes, MD

Rutgers Cancer Institute of New Jersey, New Jersey, United States